biotech

What a Wild Year It Was
for Health Care

Led by the health insurance reform law, a flurry of drug and food recalls, key medical breakthroughs and plenty of layoffs and lawsuits, 2010 proved to be an exciting -- if not always positive -- year. Here's our list of the year's biggest health stories.

Genzyme Talks Up Possible Sales of Its New MS Drug

Biotechnology company Genzyme is holding an analyst and investor meeting Monday focused on the commercial potential of its multiple sclerosis drug Campath as it tries to convince Sanofi-Aventis that it's worth more than the Paris-based pharmaceutical giant has been offering.

Tiny Spectrum Pharmaceuticals Is Getting Plenty of Attention

What's Spectrum's particular allure? Beyond being the subject of takeover rumor, it has two oncology drugs approved by the Food and Drug Administration that are already on the market, plus two other promising drugs that are in late-stage clinical trials.

Is ImmunoCellular Another Rising Star in Biotech?

Much like Dendreon, which has a promising prostate cancer drug, ImmunoCellular is developing a cancer drug. In this case, it battles brain cancer, and a Phase I trial turned in remarkable results. But unlike Dendreon, ImmunoCellular is still pretty much an unknown.

Growing Interest
in Achillion's Hepatitis Drugs

At a liver disease conference in Boston, one of the highlights is expected to be reports from Achillion about its novel hepatitis C treatments, especially ACH-1625. The buzz is growing stronger that the little biotech is attracting the attention of some players in Big Pharma.

A New Antidepressant Maker Has Lots of Folks Excited

Tiny, little-known biotech Clinical Data has developed a potential blockbuster drug called Vilazodone. If OK'd, it would be the first new depression treatment in 15 years. Its potential is so huge that several Big Pharmas are said to looking to buy the startup.

Biotechs and Big Pharma Squabble in Sweden

At a recent life-sciences conference in Stockholm, execs of several U.S. and foreign biotechs clashed with Big Pharma in a lively debate on the merits of their respective goals and products. The result, however, was a stand-off.

Sanofi Denies Offering $69-$80 Price Range to Genzyme

There's a new plot twist in the takeover battle between French pharmaceutical giant Sanofi-Aventis and U.S. drugmaker Genzyme. A regulatory filing made by Genzyme on Thursday claims Sanofi may be willing to go much higher than its current $69 bid -- a claim the French company disputes.

Is This Tiny Aussie Biotech the Next Dendreon?

Dendreon's Provenge, which targets prostate cancer, catapulted that company's stock to record highs recently. Prima Biomed's CVac works similarly, but it has the potential to target multiple forms of cancer, giving the Australian company an intriguing future.

Genzyme Rejects $18.5B Bid from Sanofi-Aventis

One of the most interesting merger and acquisition sagas of the past month is no doubt the French drugmaker Sanofi-Aventis' (SNY) courtship of rare-disease biotech Genzyme (GENZ). On Monday, Genzyme has confirmed that it has received Sanofi's unsolicited proposal of $69 per share in cash, adding its the board of directors unanimously rejected the proposal -- again.

Sanofi-Avenits Won't Boost Genzyme Bid

Pharmaceutical giant Sanofi-Aventis is unwilling to pay more than $70 a share in its bid to buy biotech firm Genzyme, media outlets reported Wednesday. If a deal can't be reached, the French drugmaker may consider alternative takeover targets.

Biotech Stocks With Upside Potential

Hilary Kramer recently recommended shares of Jazz Pharmaceuticals, which surged 16% on Wednesday before closing up just 3%. The reason: The U.S. Food and Drug Administration approved the drug, used for narcolepsy, for fibromyalgia.Kramer also recommends two other biotech medical equipment companies with upside potential.

Deutsche Bank Initiates Coverage of Biotech Stocks

Several biotech stocks were on the move Monday after Deutsche Bank initiated coverage on some of them. The bank's analyst, Robyn Karnauskas, took a generally wary view on the biotech sector, only putting buy ratings on Gilead and Dendreon.

Under the Radar: Jazz Pharmaceuticals, Dendreon, TranS1

As the stock market falls, it may seem difficult to find stocks that will do well. But Hilary Kramer, who focuses on under the radar, game changing stocks, says there are some great opportunities among biotech and medical equipment companies.

Sanofi-Aventis Opens Buyout Talks with Genzyme

French pharmaceutical giant Sanofi-Aventis sent a letter to major U.S. biotech firm Genzyme proposing a friendly takeover valued at $69 a share, or $18.4 billion. But that's significantly less than the offer of $80 a share, or $21.3 billion, that sources say Genzyme is looking for.

This Tiny Biotech Has Some Giant Backers

ZIOPHARM has enticed several major institutional investors to put their money in it. And it has an all-star group of cancer scientists joining its committee to design Phase 3 clinical trials for its chief product, Zymafos, a cancer treatment.

Cerberus Sells Talecris for $3.4 Billion

Spain may be embroiled in a credit crisis, but that hasn't stopped some of its companies from striking big deals. Take Grifols SA: The medical products developer has agreed to shell out $3.4 billion to acquire Talecris Biotherapeutics Holdings from private-equity firm Cerberus.

Abbott Experiments with a $450 Million Deal for Facet

Abbott Labs announced it would acquire Facet Biotech for $27 per share. The friendly deal, which will enhance Abbott's pharmaceutical pipeline, is expected to close in the second quarter of this year and has been approved by the boards of both companies.